Therapeutic Effectiveness of Immunoradiotherapy on Brain-metastatic BRAF/MEK Inhibitor-resistant Melanoma with Balloon Cell Change

Acta Derm Venereol. 2019 May 1;99(6):612-613. doi: 10.2340/00015555-3134.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Brain Neoplasms / enzymology
  • Brain Neoplasms / immunology
  • Brain Neoplasms / secondary
  • Brain Neoplasms / therapy*
  • Chemotherapy, Adjuvant
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • MAP Kinase Kinase Kinases / antagonists & inhibitors
  • MAP Kinase Kinase Kinases / metabolism
  • Melanoma / enzymology
  • Melanoma / immunology
  • Melanoma / secondary
  • Melanoma / therapy*
  • Mutation
  • Nivolumab / therapeutic use*
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors
  • Proto-Oncogene Proteins B-raf / genetics
  • Proto-Oncogene Proteins B-raf / metabolism
  • Radiosurgery*
  • Skin Neoplasms / enzymology
  • Skin Neoplasms / immunology
  • Skin Neoplasms / pathology
  • Skin Neoplasms / therapy*
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Immunological
  • Protein Kinase Inhibitors
  • Nivolumab
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • MAP Kinase Kinase Kinases